Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to Ophthalmology Times Europe.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
Glaucoma
Retina
Award entries
 
 
Survey

Do you repeat SLT treatment more than twice in the same section of TM?

Yes
50%
No
50%

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.


April 30, 2014
Clinical research
Glaucoma changes rapid contrast adaptation
Glaucoma, but not ageing, changes rapid contrast adaptation, which is vital to visual processing in natural visual environments, say researchers from Australia in a recent study. More...
Disease management
Ocriplasmin limited as a macular hole management option
For a small percentage of patients who have macular holes, ocriplasmin injection represents an adequate treatment option; however, for most patients, pars plana vitrectomy will likely remain the treatment of choice. More...
XOVA competition
Award entries accepted to help solve unmet eye care needs
The eXcellence in Ophthalmology Vision Award (XOVA) competition is accepting entries until 30 June. More...
Event Profile
120th Congress of the French Society of Ophthalmology
Dates: 10–13 May 2014
Venue: Palais des Congrès, Porte Maillot, Paris
The SFO’s annual congress will bring together more than 8000 attendees, 100 exhibitors, 60 scientific sessions, 300 oral communications, 60 workshops, symposia with foreign Societies, 450 e-posters and e-films … Hot Topics will be discussed, a live surgery session on Monday 12th will be programmed, and a specific space (2nd floor) will be dedicated to technology and communication.
Read more:
Ranibizumab leading the anti-VEGF evolution
Considerations and new perspectives in anti-VEGF therapy. Read more:
Choosing and using the AcrySof IQ ReSTOR IOL family
Customize
d options for individual patients. Read more:
The Safety of anti-VEGF Therapy
Under the microscope, in trials and in clinical practice. Read more: